New Guideline: Treatment of Chronic Hepatitis C Virus (HCV) Infection with Direct-Acting Antivirals (DAAs)
The Office of the Medical Director, New York State Department of Health (NYSDOH) AIDS Institute (AI), is pleased to announce the publication of a new clinical practice guideline: Treatment of Chronic HCV Infection with Direct-Acting Antivirals (DAAs).
Developed by the NYSDOH AI Hepatitis C Virus Infection Guideline Committee, this guideline provides clinicians in New York State with the information and evidence-based recommendations they need to treat patients with chronic HCV infection.
The availability of safe and effective oral DAA regimens has revolutionized HCV care for many people with chronic HCV infection. To benefit from treatment, candidates must be: screened for and diagnosed with HCV infection, engaged in care, and have access to treatment that is managed by an informed clinician. Toward that end, this new guideline covers all aspects of HCV care, with the aims of increasing the use of curative DAA therapies among NYS residents living with HCV infection and reducing the growing burden of mortality associated with chronic HCV infection.